Neurocrine Biosciences, Inc. NBIX

NAS: NBIX | ISIN: US64125C1099   13/03/2026
129,78 USD (+1,57%)
(+1,57%)   13/03/2026

10 maart 2026 · Neurocrine Biosciences to Present at the Stifel 2026 Virtual CNS Forum · Persbericht

6 maart 2026 · BetterInvesting™ Magazine Update on Equifax Inc. (NYSE: EFX) and Neurocrine Bio In. (NASDAQ: NBIX) · Persbericht

24 februari 2026 · Neurocrine Biosciences to Present at Upcoming Investor Conferences in March · Persbericht

11 februari 2026 · Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026 · Persbericht

26 januari 2026 · Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia · Persbericht

21 januari 2026 · Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2025 Financial Results · Persbericht

15 januari 2026 · Neurocrine Biosciences Presents Head-to-Head INGREZZA® (valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR · Persbericht

5 januari 2026 · Neurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference · Persbericht

22 december 2025 · Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy · Persbericht

16 december 2025 · Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology · Persbericht

9 december 2025 · Neurocrine Biosciences to Host R&D Day on December 16 · Persbericht

20 november 2025 · Neurocrine Biosciences Announces Publication of Landmark Narrative Review on FDA-Approved VMAT2 Inhibitors Demonstrating Unique Profile of INGREZZA® (valbenazine) Capsules · Persbericht

11 november 2025 · Neurocrine Biosciences to Present at Upcoming Investor Conferences · Persbericht

10 november 2025 · Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-1070770 in Adults with Major Depressive Disorder · Persbericht

28 oktober 2025 · Neurocrine Biosciences Reports Third Quarter 2025 Financial Results · Persbericht

17 oktober 2025 · Neurocrine Biosciences Presents New KINECT® 4 Post-Hoc Analysis Demonstrating Rapid and Sustained Therapeutic Efficacy of INGREZZA® (valbenazine) 40 mg Capsules · Persbericht

7 oktober 2025 · Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2025 Financial Results · Persbericht

6 oktober 2025 · Neurocrine Biosciences Appoints Mike Sibley as Senior Vice President, General Manager of Neuropsychiatry Franchise · Persbericht

6 oktober 2025 · Neurocrine Biosciences Presents New Three-Year Data Demonstrating Sustained Clinical Benefits and Established Safety Profile of INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea · Persbericht

23 september 2025 · Neurocrine Biosciences Presents New Post-Hoc Analysis: Treatment with INGREZZA® (valbenazine) Capsules Achieves Earlier Remission of Tardive Dyskinesia Symptoms While Reducing Patient-Reported Disease Burden · Persbericht

Mijn selecties